Last reviewed · How we verify

Asceniv™ — Competitive Intelligence Brief

Asceniv™ (Asceniv™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIG). Area: Immunology.

marketed Intravenous immunoglobulin (IVIG) Polyclonal immunoglobulins (IgG) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Asceniv™ (Asceniv™) — ADMA Biologics, Inc.. Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Asceniv™ TARGET Asceniv™ ADMA Biologics, Inc. marketed Intravenous immunoglobulin (IVIG) Polyclonal immunoglobulins (IgG)
Flebogamma 5% DIF Flebogamma 5% DIF Instituto Grifols, S.A. marketed Intravenous immunoglobulin (IVIG) Fc receptors, pathogenic antigens and antibodies
Gammaplex (5%) Gammaplex (5%) Bio Products Laboratory marketed Intravenous immunoglobulin (IVIG) Fc receptors and complement system (indirect mechanism via antibody delivery)
IgPro IgPro CSL Behring marketed Intravenous immunoglobulin (IVIG) Multiple pathogenic antigens (polyvalent)
PRIVIGEN (CSL Behring) PRIVIGEN (CSL Behring) Hospices Civils de Lyon marketed Intravenous immunoglobulin (IVIg) Fc receptors, complement system, pathogenic antigens and antibodies
IgG Next Generation (BT595) IgG Next Generation (BT595) Biotest phase 3 Intravenous immunoglobulin (IVIG)
RI-002 RI-002 ADMA Biologics, Inc. phase 3 Intravenous immunoglobulin (IVIG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous immunoglobulin (IVIG) class)

  1. CSL Limited · 4 drugs in this class
  2. Instituto Grifols, S.A. · 2 drugs in this class
  3. Bio Products Laboratory · 2 drugs in this class
  4. ADMA Biologics, Inc. · 2 drugs in this class
  5. Grifols Biologicals, LLC · 1 drug in this class
  6. Grifols Therapeutics LLC · 1 drug in this class
  7. Kedrion S.p.A. · 1 drug in this class
  8. Octapharma · 1 drug in this class
  9. Oslo University Hospital · 1 drug in this class
  10. SK Plasma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Asceniv™ — Competitive Intelligence Brief. https://druglandscape.com/ci/asceniv. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: